This fast track antibody is not yet fully characterized. It is subject to these terms and conditions

Overview

Properties

Applications

Fast track antibodies constitute a diverse group of products that have been released to accelerate your research, but are not yet fully characterized. They have all been affinity purified and show high titre values against the immunizing peptide (by ELISA). Fast track terms of use

Application Abreviews Notes
ELISA Use at an assay dependent concentration. This antibody gave a positive result in ELISA against the immunizing peptide (ab43767).
IHC-FoFr Use at an assay dependent concentration. The antibody has been successfully used in IHC-FoFr on rat sections. However, this is preliminary data and customers may get variable results.
CHIPseq Use at an assay dependent concentration. PubMed: 22180461

Target

  • FunctionSequence-specific DNA-binding transcription factor. Binds to two specific DNA sites located in the promoter region of HOXA4.
  • Involvement in diseaseDefects in EGR2 are a cause of congenital hypomyelination neuropathy (CHN) [MIM:605253]. Inheritance can be autosomal dominant or recessive. Recessive CHN is also known as Charcot-Marie-Tooth disease type 4E (CMT4E). CHN is characterized clinically by early onset of hypotonia, areflexia, distal muscle weakness, and very slow nerve conduction velocities.
    Defects in EGR2 are a cause of Charcot-Marie-Tooth disease type 1D (CMT1D) [MIM:607678]. CMT1D is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT1 group are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.
    Defects in EGR2 are a cause of Dejerine-Sottas syndrome (DSS) [MIM:145900]; also known as Dejerine-Sottas neuropathy (DSN) or hereditary motor and sensory neuropathy III (HMSN3). DSS is a severe degenerating neuropathy of the demyelinating Charcot-Marie-Tooth disease category, with onset by age 2 years. DSS is characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome.
  • Sequence similaritiesBelongs to the EGR C2H2-type zinc-finger protein family.
    Contains 3 C2H2-type zinc fingers.
  • Post-translational
    modifications
    Ubiquitinated by WWP2 leading to proteasomal degradation.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • AT591 antibody
    • CMT1D antibody
    • CMT4E antibody
    • DKFZp686J1957 antibody
    • E3 SUMO-protein ligase EGR2 antibody
    • Early growth response 2 antibody
    • Early growth response protein 2 antibody
    • EGR-2 antibody
    • egr2 antibody
    • EGR2_HUMAN antibody
    • FLJ14547 antibody
    • KROX 20 Drosophila homolog antibody
    • Krox 20 homolog Drosophila antibody
    • KROX-20, Drosophila, homolog (early growth response-2) antibody
    • KROX20 antibody
    • Krox20 protein antibody
    • Zinc finger protein Krox-20 antibody
    see all

Anti-EGR2 antibody images

This Fast-Track antibody is not yet fully characterised. These images represent inconclusive preliminary data.

  • IHC-FoFr image of EGR2 staining on rat cerebral cortex. The sections used came from animals perfused fixed with Paraformaldehyde 4%, in phosphate buffer 0.2M. Following postfixation in the same fixative overnight, the brains were cryoprotected in sucrose 30% overnight. Brains were then cut using a cryostat and the immunostainings were performed using the ‘free floating’ technique. The antibody has been successfully used in IHC-FoFr on rat sections. However, this is preliminary data and customers may get variable results.

    See Abreview

References for Anti-EGR2 antibody (ab43020)

This product has been referenced in:
  • Yue Y  et al. Low-intensity pulsed ultrasound upregulates pro-myelination indicators of Schwann cells enhanced by co-culture with adipose-derived stem cells. Cell Prolif 49:720-728 (2016). Read more (PubMed: 27625295) »
  • Guo L  et al. The protein kinase A regulatory subunit R1A (Prkar1a) plays critical roles in peripheral nerve development. J Neurosci 33:17967-75 (2013). Read more (PubMed: 24227708) »

See all 5 Publications for this product

Product Wall

Application Immunohistochemistry (Frozen sections)
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 25°C
Sample Mouse Tissue sections (nerve)
Specification nerve
Permeabilization Yes - 0.5% Triton X 100
Fixative Paraformaldehyde
Username

Abcam user community

Verified customer

Submitted Jun 20 2013

Application Immunohistochemistry (PFA perfusion fixed frozen sections)
Sample Rat Tissue sections (Brain - cerebral Cortex)
Specification Brain - cerebral Cortex
Fixative Paraformaldehyde
Username

Dr. Sophie Pezet

Verified customer

Submitted Sep 08 2010

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"